Your browser doesn't support javascript.
loading
Risk-Adapted Starting Age for Personalized Colorectal Cancer Screening: Validated Evidence From National Population-Based Studies.
Dong, Xuesi; Luo, Zilin; Wu, Zheng; Hang, Dong; Xia, Changfa; Wang, Fei; Zheng, Yadi; Yu, Yiwen; Xu, Yongjie; Cao, Wei; Qin, Chao; Zhao, Liang; Li, Jiang; Ren, Jiansong; Shi, Jufang; Du, Mulong; Chen, Wanqing; Shen, Hongbing; Li, Ni; He, Jie.
Afiliação
  • Dong X; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Luo Z; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Wu Z; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Hang D; Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Xia C; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Wang F; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Zheng Y; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Yu Y; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Xu Y; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Cao W; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Qin C; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Zhao L; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Li J; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Ren J; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Shi J; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Du M; Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Chen W; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • Shen H; Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Li N; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implemen
  • He J; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: hejie@cicams.ac.cn.
Clin Gastroenterol Hepatol ; 21(3): 819-826.e13, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36403728
ABSTRACT
BACKGROUND &

AIMS:

A one-size-fits-all approach to colorectal cancer (CRC) screening that does not account for CRC risk factors is not conducive to personalized screening. On the basis of the principle of equal management of equal risks, we aimed to tailor and validate risk-adapted starting ages of CRC screening for individuals with different CRC risk factors.

METHODS:

A multi-center community-based population cohort (N = 3,165,088) was used to evaluate the starting age of CRC screening with comprehensive consideration of risk factors. Age-specific 10-year cumulative risk curves were used to determine when individuals at greater risk for CRC reached the same risk level as the 50-year-old general population, which is currently the recommended starting age for CRC screening in China.

RESULTS:

During the study follow-up period (2013-2021), 4,840 incident CRCs were recorded. Family history of CRC, adverse lifestyle, and comorbidities demonstrated heterogeneous associations with CRC risk (hazard ratios, 1.05-1.55; P < .05). Men and women with CRC family history and at least 2 risk factors reached the standard benchmark risk (0.28%) for screening at the age of 40, 10 years earlier than their peers without risk factors in the general population. Proposed starting ages for CRC screening were validated in an independent community-based population cohort (N = 1,023,367).

CONCLUSIONS:

We determined a risk-adapted CRC screening starting age for individuals with various CRC risk factors. Earlier, personalized screening based on these findings could allow for scarce health resources to be dedicated to individuals who benefit most.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Detecção Precoce de Câncer Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Detecção Precoce de Câncer Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article